Abstracts tagged "proteomics"

Abstract Number: 0763 • ACR Convergence 2020
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Nora Petrovská¹, Monika Gregová¹, Jiří Baloun², Petra Hánová², Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…
Abstract Number: 0936 • ACR Convergence 2020
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Andrea Fava¹, Jill Buyon², Chandra Mohan³, Ting Zhang³, H. Michael Belmont⁴, Peter Izmirly⁵, Robert Clancy⁶, Jose Monroy-Trujillo⁷, Celine Berthier⁸, Anne Davidson⁹, Nir Hacohen¹⁰, David Wofsy¹¹, Deepak Rao¹², Soumya Raychaudhuri¹³, The Accelerating Medicines Partnership in SLE Network¹⁴, William Apruzzese¹⁵ and Michelle Petri¹⁶, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³UT Houston, Houston, ⁴New York University, New York, NY, ⁵Department of Medicine, New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, ⁷Johns Hopkins University, Baltimore, ⁸University of Michigan, Ann Arbor, ⁹Northwell Health, New York, ¹⁰Broad Institute, Boston, ¹¹University of California San Francisco, San Francisco, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁴Multiple Institutions, Multiple Cities, ¹⁵., Boston, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize…
Abstract Number: 0953 • ACR Convergence 2020
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Jacob Wozniak¹, Ru Bryan², David Gonzalez³ and Robert Terkeltaub⁴, ¹UC San Diego, San Diego, CA, ²UCSD, San Diego, CA, ³UC San Diego, San Diego, CO, ⁴VA Medical Center/UC San Diego, San Diego, CA
Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…
Abstract Number: 1359 • ACR Convergence 2020
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
Thierry Sornasse¹, In-Ho Song², Timothy Radstake³ and Dennis McGonagle⁴, ¹AbbVie Immunology Clinical Development, Redwood City, ²AbbVie Inc., North Chicago, IL, ³AbbVie Immunology Clinical Development, North Chicago, ⁴The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to…
Abstract Number: 1809 • ACR Convergence 2020
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
Fabien Vincent¹, Jannina Ong¹, Alberta Hoi², Sarah Boyd¹, Hieu Nim¹ and Eric Morand³, ¹Monash University, Clayton, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
Abstract Number: 1822 • ACR Convergence 2020
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
Shiliang Wang¹, Richard Furie², Mary Anne Dooley³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Gerald Appel¹⁰, David Jayne¹¹, Sarah Hu¹², Sheng Gao¹³ and Michael Maldonado¹², ¹Bristol-Myers Squibb Company (at the time of analysis), Princeton, NJ, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of North Carolina, Chapel Hill, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁷University of Padua, Padua, Italy, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ¹²Bristol-Myers Squibb Company, Princeton, NJ, ¹³Bristol-Myers Squibb Company (at the time of analysis), Princeton, NY
Background/Purpose: The ALLURE study compared efficacy and safety of abatacept (ABA) vs placebo (PBO) on background MMF and CS for the treatment of active proliferative…
Abstract Number: 1909 • ACR Convergence 2020
High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Nicolas Wisniacki³, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: Simultaneous analysis of multiple proteins in biological fluids offers insight into the pathogenesis of SSc. Here, we report a proteomic analysis of plasma and…
Abstract Number: 0029 • ACR Convergence 2020
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Emma Weeding¹, Andrea Fava¹, Jill Buyon², H. Michael Belmont³, Peter Izmirly⁴, Robert Clancy⁵, Jose Monroy-Trujillo⁶, Derek Fine⁶, William Apruzzese⁷, Harald Mischak⁸ and Michelle Petri⁹, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, ⁷., Boston, ⁸Multiple Institutions, Glasgow, United Kingdom, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…
Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Ana Fernandes¹, Atlas Mashayekhi Sardoo², Miguel Bernardes³, Patrícia Pinto⁴, Helena Santos⁵, João Lagoas Gomes⁶, José Tavares-Costa⁷, José A. P. da Silva⁸, João Madruga-Dias⁹, Alexandra Bernardo¹⁰, Jean-Charles Gaillard¹¹, Lúcia Domingues¹², Sara Maia¹², Jean Armengaud¹¹, Jaime C. Branco¹³, Ana Varela Coelho¹⁴ and Fernando Pimentel-Santos¹⁵, ¹1.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa; 2.Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal, Oeiras, Portugal, ²3. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³4.Centro Hospitalar de S. João (Rheumatology Department) , Porto, Portugal, Porto, Portugal, ⁴5. Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, ⁵6.Instituto Português de Reumatologia (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ⁶7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ⁷8.Unidade Local de Saúde do Alto Minho (Rheumatology Department), Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁸9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ⁹10.Centro Hospital Médio Tejo (Rheumatology Department), Torres Novas, Portugal, Dublin, Ireland, ¹⁰5.Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, ¹¹11.Centre d énergie atomique (Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI)), Avignon, France, Avignon, France, ¹²3.CEDOC, NOVA Medical School. Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ¹³3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ¹⁴1.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa, Oeiras, Portugal, Oeiras, Portugal, ¹⁵3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…
Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Sara Rahmati¹, Fatima Abji¹, Proton Rahman² and Vinod Chandran³, ¹University Health Network, Toronto, ON, Canada, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Sebastian Unizony¹, Robert Morris², Johannes Kreuzer², Wilhelm Haas² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
Abstract Number: 0752 • ACR Convergence 2020
Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
Liam O'Neil¹, Vidyanand Anaparti¹, Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹ and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Though targeted therapeutics have improved outcomes in Rheumatoid Arthritis (RA) treatment, the understanding of the underlying biological mechanisms that mediate inflammatory arthritis in RA…
Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Lucía González-Rodríguez¹, Valentina Calamia ¹, Rocío Paz-González ¹, Patricia Fernández-Puente ¹, Cristina Ruiz-Romero ¹, Antonio Julià ², Antonio Fernández-Nebro ³, Jesús Tornero ⁴, Sara Marsal ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ²Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ³UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Andalucia, Spain, ⁴Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁵Vall d’Hebron Hospital, Barcelona, Catalonia, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1722 • 2019 ACR/ARP Annual Meeting
Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Peter Gorevic¹, Frank Eng ², Andrea Branch ³, Ahmed Elshamy ⁴, Erin Doyle ² and Thomas Schiano ², ¹Mount Sinai Hospital, New York, ²Mount Sinai Medical Center, New York, ³Mount Sinai Medical School, New York, ⁴California Northstate University, Sacramento
Background/Purpose: BACKGROUND. Mixed Cryoglobulins (MCs) are cold precipitable Rheumatoid Factors (RFs) that provide a biomarker for immune complex formation, particularly associated with chronic Hepatitis C…
Abstract Number: 1944 • 2019 ACR/ARP Annual Meeting
Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
María Camacho-Encina¹, Vanesa Balboa-Barreiro ², Rocío Paz-González ³, Valentina Calamia ³, Lucía Lourido ⁴, Patricia Fernández-Puente ³, Cristina Ruiz-Romero ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ²Grupo de Investigación de Reumatología (GIR), INIBIC-Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Galicia, Spain, ³Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ⁴Proteomics Group-ProteoRed/ISCIII, RIER, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ⁵Proteomics Group-ProteoRed/ISCIII, CIBER-BBN, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is the most prevalent rheumatic disorder of the middle-age population. The lack of sensitive diagnostics methods led to an identification of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].